abrdn Life Sciences Investors
HQL
$12.61
$0.292.35%
| Weiss Ratings | HQL-NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Fair | |||
| Reward Grade | C | |||
| Risk Index | Fair | |||
| Risk Grade | C- | |||
| Company Info | HQL-NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Provider | abrdn Inc. | |||
| Manager/Tenure (Years) | Jason C. Akus (1) | |||
| Website | http://www.abrdn.com/us | |||
| Fund Information | HQL-NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Fund Name | abrdn Life Sciences Investors | |||
| Category | Health | |||
| Sub-Category | Healthcare Sector Equity | |||
| Prospectus Objective | Specialty - Health | |||
| Inception Date | May 08, 1992 | |||
| Open/Closed To New Investors | Open | |||
| Minimum Initial Investment | -- | |||
| Minimum Subsequent Investment | -- | |||
| Front End Fee | -- | |||
| Back End Fee | -- | |||
| Dividends and Shares | HQL-NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Yield | 0.00% | |||
| Dividend | HQL-NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Yield (Forward) | 0.47% | |||
| Asset Allocation | HQL-NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Cash | 6.30% | |||
| Stock | 85.90% | |||
| U.S. Stock | 73.97% | |||
| Non-U.S. Stock | 11.93% | |||
| Bond | 0.00% | |||
| U.S. Bond | 0.00% | |||
| Non-U.S. Bond | 0.00% | |||
| Preferred | 6.98% | |||
| Convertible | 0.26% | |||
| Other Net | 0.56% | |||
| Price History | HQL-NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 5.22% | |||
| 30-Day Total Return | -8.29% | |||
| 60-Day Total Return | -12.05% | |||
| 90-Day Total Return | -10.99% | |||
| Year to Date Total Return | -7.24% | |||
| 1-Year Total Return | -0.56% | |||
| 2-Year Total Return | 0.40% | |||
| 3-Year Total Return | 7.73% | |||
| 5-Year Total Return | 7.28% | |||
| Price | HQL-NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Closing Price | -- | |||
| 1-Month Low Price | $10.87 | |||
| 1-Month High Price | $13.26 | |||
| 52-Week Low Price | $10.87 | |||
| 52-Week Low Price (Date) | Apr 08, 2025 | |||
| 52-Week High Price | $15.78 | |||
| 52-Week High Price (Date) | Aug 21, 2024 | |||
| NAV | HQL-NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Nav | $13.82 | |||
| 1-Month Low NAV | $12.00 | |||
| 1-Month High NAV | $14.71 | |||
| 52-Week Low NAV | $12.00 | |||
| 52-Week Low NAV (Date) | Apr 08, 2025 | |||
| 52-Week High NAV | $17.36 | |||
| 52-Week High Price (Date) | Aug 21, 2024 | |||
| Beta / Standard Deviation | HQL-NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.87 | |||
| Standard Deviation | 14.92 | |||
| Balance Sheet | HQL-NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Total Assets | 395.84M | |||
| Operating Ratios | HQL-NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Expense Ratio | 1.35% | |||
| Turnover Ratio | 46.00% | |||
| Performance | HQL-NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Last Bull Market Total Return | 13.58% | |||
| Last Bear Market Total Return | -8.89% | |||